Keenova Therapeutics plc: Edema trials

The registry lists 12 Edema studies with Keenova Therapeutics plc as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 5Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFPCompletedNCT03675685Phase 1Results posted
• Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)CompletedNCT03632993Phase 2Results posted
• Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)CompletedNCT03526549Phase 3Results posted
• Effectiveness and Safety of EN3835 in the Treatment of Cellulite in WomenCompletedNCT03446781Phase 3Results posted
• Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenCompletedNCT03428750Phase 3Results posted
• Safety and Effectiveness of EN3835 in the Treatment of EFP in WomenCompletedNCT03329989Phase 2Results posted
• EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)CompletedNCT02942160Phase 2Results posted
• EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)CompletedNCT02724644Phase 2Results posted
• A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic PanniculopathyCompletedNCT01987986Phase 2Results posted
• Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)CompletedNCT04381117
• Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenCompletedNCT03893890
• The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)CompletedNCT01518907Phase 1